VIRX (Viracta Therapeutics) Shares Outstanding (Basic Average): 39.57 Mil (As of Sep. 2024)


What is Viracta Therapeutics Shares Outstanding (Basic Average)?

Viracta Therapeutics VIRX Shares Outstanding (Basic Average) is 39.57 Mil as of Sep. 2024.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Viracta Therapeutics's average basic shares outstanding for the quarter that ended in Sep. 2024 was 39.57 Mil.

Viracta Therapeutics  (OTCPK:VIRX) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

Viracta Therapeutics Shares Outstanding (Basic Average) Related Terms

Viracta Therapeutics Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for Viracta Therapeutics's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics Shares Outstanding (Basic Average) Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Basic Average)
37.00 31.87 37.79 38.62

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.68 38.79 39.32 39.41 39.57

Viracta Therapeutics Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 39.57 Mil mean?
Viracta Therapeutics (VIRX) has a Shares Outstanding (Basic Average) of 39.57 Mil as of Sep. 2024. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Viracta Therapeutics and its competitors.
Is Viracta Therapeutics' Shares Outstanding (Basic Average) too high?
Viracta Therapeutics' current Shares Outstanding (Basic Average) is 39.57 Mil.
How does Viracta Therapeutics' Shares Outstanding (Basic Average) compare to TSOI and CYTOF?
Viracta Therapeutics' Shares Outstanding (Basic Average) of 39.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Viracta Therapeutics and its competitors. Viracta Therapeutics's current Shares Outstanding (Basic Average) is 39.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viracta Therapeutics stock overvalued right now?
Viracta Therapeutics (VIRX) has a current Shares Outstanding (Basic Average) of 39.57 Mil. The current Shares Outstanding (Basic Average) is 39.57 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Viracta Therapeutics (VIRX), the current Shares Outstanding (Basic Average) is 39.57 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viracta Therapeutics Business Description

Address 2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.